This medication is a folate analogue metabolic inhibitor, prescribed for refractory peripheral T-cell lymphoma (PTCL). It works by killing certain types of cancer cells.
IV- The recommended dose is 30 mg/m2 over 3-5 minutes infusion.
It comes as a solution for injection, to be administered by a healthcare provider into the vein.
• Caution should be exercised in patients with history of liver or kidney impairment, any allergy, children, during pregnancy and breastfeeding.
• Avoid use in patients with end stage renal disease including those undergoing dialysis.
• It may reduce platelet counts; avoid injury or bruising.
• Avoid becoming dehydrated while taking this medication.
• Monitor complete blood cell counts and liver and kidney function regularly while taking this medication.
• Patient may develop with increased risk of tumor lysis syndrome (TLS) with the following symptoms: irregular heartbeat, fainting, decreased urination, muscle weakness or cramps, nausea, vomiting, diarrhea, or loss of appetite; or sluggishness. If it is so consult with your doctor.
• Most Common : Decrease in platelet counts and white blood cells, inflammation of mucous, nausea, fatigue, anemia, constipation, fever, fluid retention, cough, nose bleed, vomiting, diarrhea, difficulty in breathing, loss of appetite, rash, itching, throat pain, liver function test abnormal, abdominal pain, pain in extremity, back pain, night sweats, weakness, fast heart rate.
Avoid excess dosage.
Store in refrigerator at 2-8°C.
Subscribe to our Free Newsletters!